Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9331-9337

  Backlund, Michael G ^a   Mann, Jason R ^b   Holla, Vijaykumar R ^c   Shi, Qiong ^b   Daikoku, Takikoku ^a   Dey, Sudhansu K ^a   DuBois, Raymond N ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; BUTYRIC ACID; EPIDERMAL GROWTH FACTOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR SNAIL; VALPROIC ACID;

15 PGDH GENE; ADENOMA; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HDAC GENE; HDAC2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANIMALS; COLONIC NEOPLASMS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 56449114200     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2893     Document Type: Article

References (32)

1. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
2. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
3. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002; 42:55-80.
4. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122: 518-23.
5. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002;53:35-57.
6. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory druginduced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-8.
7. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003;24:985-90.
8. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 2004;6:285-95.
9. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 2002;68-69:483-93.
10. Pichaud F, Delage-Mourroux R, Pidoux E, Jullienne A, Rousseau-Merck MF. Chromosomal localization of the type-I 15-PGDH gene to 4q34-q35. Hum Genet 1997;99: 279-81.
11. Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 2002;8:91-2.
12. Rao CV, Wang CX, Simi B, et al. Enhancement of experimental colon cancer by genistein. Cancer Res 1997;57:3717-22.
13. Tong M, Tai HH. Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun 2000;276:77-81.
14. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72.
15. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-23.
16. Wolf I, O'Kelly J, Rubinek T, et al. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66:7818-23.
17. Mann JR, Backlund MG, Buchanan FG, et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006;66:6649-56.
18. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468-73.
19. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103: 12098-102.
20. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-7.
21. Nelson JE, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 2006;34:e2.
22. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133:2485-93S.
23. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004;24:306-19.
24. Tripathi MK, Misra S, Khedkar SV, et al. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J Biol Chem 2005;280: 17163-71.
25. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5: 455-63.
26. Tong M, Ding Y, Tai HH. Histone deacetylase inhibitors and transforming growth factor-β induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol 2006;72:701-9.
27. Bailey CK, Misra S, Mittal MK, Chaudhuri G. Human SLUG does not directly bind to CtBP1. Biochem Biophys Res Commun 2007;353:661-4.
28. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/ WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
29. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-58.
30. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
31. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
32. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65:4218-27.